MX2012001746A - Metodos de diagnostico y tratamiento de autismo. - Google Patents

Metodos de diagnostico y tratamiento de autismo.

Info

Publication number
MX2012001746A
MX2012001746A MX2012001746A MX2012001746A MX2012001746A MX 2012001746 A MX2012001746 A MX 2012001746A MX 2012001746 A MX2012001746 A MX 2012001746A MX 2012001746 A MX2012001746 A MX 2012001746A MX 2012001746 A MX2012001746 A MX 2012001746A
Authority
MX
Mexico
Prior art keywords
protein
mother
antibodies
asd
fetus
Prior art date
Application number
MX2012001746A
Other languages
English (en)
Inventor
Water Judy Van De
Daniel Braunschweig
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2012001746A publication Critical patent/MX2012001746A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invención provee métodos de diagnóstico para determinar el riesgo de desarrollar una alteración de espectro de autismo(ASD) en un feto o niño al detectar en una muestra biológica de la madre anticuerpos que se enlazan a uno o más biomarcadores seleccionados del grupo que consiste de lactato deshidrogenada (LDH), guanina desaminasa (GDA), proteína 1 mediadora de respuesta de colapsina (CRMP1), fosfoproteína 1 inducida por estrés (STIP1), sub-unidad alfa de la proteína de enlace de actina de extremos con púas Cap Z (CAPZA2), proteína de enlace de bloque Y (YBX1), factor de traducción y alargamiento eucarióntico 1A1 (EEF1A1), proteína Tau microtúbulo-asociada (MAPT), proteína 2 semejante a dihidropirimidinasa (DPYSL2), proteína semejante a dinamina 1 (DNM1L), radixina (RDX), moesina (MSN) y ezrina (EZR). La invención provee además métodos para impedir o reducir el riesgo de que un feto o niño desarrolle una ASD al administrar a la madre un agente que bloquea el enlace de anticuerpos maternos a uno o más biomarcadores fetales enlistados anteriormente o al remover de la madre anticuerpos que se enlazan a uno o más biomarcadores fetales.
MX2012001746A 2009-08-14 2010-08-12 Metodos de diagnostico y tratamiento de autismo. MX2012001746A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23411009P 2009-08-14 2009-08-14
PCT/US2010/045343 WO2011019929A1 (en) 2009-08-14 2010-08-12 Methods of diagnosing and treating autism

Publications (1)

Publication Number Publication Date
MX2012001746A true MX2012001746A (es) 2012-03-21

Family

ID=43101657

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012001746A MX2012001746A (es) 2009-08-14 2010-08-12 Metodos de diagnostico y tratamiento de autismo.
MX2019014978A MX2019014978A (es) 2009-08-14 2012-02-09 Metodos de diagnostico de autismo in vitro.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019014978A MX2019014978A (es) 2009-08-14 2012-02-09 Metodos de diagnostico de autismo in vitro.

Country Status (9)

Country Link
US (3) US8383360B2 (es)
EP (2) EP3444613B1 (es)
JP (2) JP5823964B2 (es)
CN (2) CN102576022B (es)
CA (1) CA2771102C (es)
DK (2) DK2464976T3 (es)
ES (1) ES2875764T3 (es)
MX (2) MX2012001746A (es)
WO (1) WO2011019929A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771102C (en) 2009-08-14 2019-10-15 The Regents Of The University Of California Methods of diagnosing and treating autism
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
CN102831856B (zh) * 2012-07-17 2016-04-13 联想(北京)有限公司 一种控制方法及电子设备
JP2014113108A (ja) * 2012-12-11 2014-06-26 Tokyo Medical Univ タンパク質の可溶化活性を有する多量体タンパク質およびその用途
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US9176113B1 (en) * 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
ES2964981T3 (es) 2015-06-26 2024-04-10 Univ California Péptidos antigénicos y usos de los mismos para diagnosticar y tratar el autismo
US10654919B2 (en) 2015-10-05 2020-05-19 The Feinstein Institutes For Medical Research Inhibition of autism spectrum disorder using decoy antigens to maternal brain-reactive antibodies
CN105652016A (zh) * 2016-01-28 2016-06-08 深圳大学 一种孤独症检测标志物及其检测方法
JP6830578B2 (ja) * 2016-09-01 2021-02-17 国立大学法人筑波技術大学 自閉症スペクトラム障害の判定方法、自閉症スペクトラム障害の判定用キットおよび測定データ取得方法
CN107058561A (zh) * 2017-05-04 2017-08-18 深圳市英马诺生物科技有限公司 自闭症生物标志物及其应用
JP7437303B2 (ja) * 2017-12-29 2024-02-22 アボット・ラボラトリーズ 外傷性脳損傷を診断及び査定するための、新規のバイオマーカー及び方法
CN109813912B (zh) * 2019-01-04 2021-12-28 深圳大学 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用
WO2021108379A1 (en) * 2019-11-25 2021-06-03 The Regents Of The University Of California Antigenic neuron specific enolase peptides for diagnosing and treating autism
CN113238045B (zh) * 2021-04-27 2021-12-28 南方医科大学南方医院 Crmp2及抗crmp2抗体的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
CN1123771C (zh) * 1996-06-11 2003-10-08 财团法人工业技术研究院 一种急性心肌梗塞检测试剂盒
DE69735601T2 (de) 1996-11-29 2007-10-18 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Anordnungen von unabhängig voneinander ansteuerbaren, gestützten flüssigbilayer-membranen und ihre anwendungsverfahren
US7030098B2 (en) 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
CN1313342A (zh) * 2001-02-28 2001-09-19 南京医科大学 人睾丸新型乳酸脱氢酶a基因编码蛋白
AU2002305861A1 (en) 2001-06-08 2002-12-23 Incyte Genomics Inc. Intracellular signaling molecules
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP2301552A1 (en) 2001-11-21 2011-03-30 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
EP1583504A4 (en) 2002-12-26 2008-03-05 Cemines Llc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER
US7452678B2 (en) * 2003-06-24 2008-11-18 Bristol-Myers Squibb Company Identification of biomarkers for liver toxicity
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
EP2514826A3 (en) * 2003-11-21 2013-04-03 Revivicor Inc. Use of interfering RNA molecules to down regulate the expression of specific genes or family of genes
CA2598889A1 (en) 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
US7604948B2 (en) * 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
WO2006121912A2 (en) 2005-05-05 2006-11-16 The Regents Of The University Of California Diagnostic methods for the detection of risk of neurodevelopmental disorders
GB0524609D0 (en) 2005-12-02 2006-01-11 Univ Cambridge Tech Methods of monitoring and diagnosing psychotic disorders and of identifying biomarkers for psychotic disorders
GB0602992D0 (en) 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
WO2008070311A2 (en) * 2006-10-20 2008-06-12 Gene Logic, Inc. Gene expression profiling of parkinson's disease
JP5298858B2 (ja) 2007-02-16 2013-09-25 株式会社島津製作所 上皮性卵巣癌の組織型識別マーカー、及びそれを用いた組織型に基づく上皮性卵巣癌の罹患の識別法
US7741464B2 (en) 2007-03-23 2010-06-22 Advpharma Inc. Compositions and methods of using CRMP-1 and its fragments for treating cancer
WO2009075883A2 (en) 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Glycoprotein cancer biomarker
CA2771102C (en) 2009-08-14 2019-10-15 The Regents Of The University Of California Methods of diagnosing and treating autism
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神***症的方法
US20140134187A1 (en) 2012-06-25 2014-05-15 The Johns Hopkins University Therapeutic and diagnostic methods for autism spectrum disorders and other conditions
ES2964981T3 (es) 2015-06-26 2024-04-10 Univ California Péptidos antigénicos y usos de los mismos para diagnosticar y tratar el autismo

Also Published As

Publication number Publication date
EP3444613A1 (en) 2019-02-20
CN105911275B (zh) 2018-06-29
EP2464976B1 (en) 2018-11-21
US10520499B2 (en) 2019-12-31
JP2015180897A (ja) 2015-10-15
US9529001B2 (en) 2016-12-27
WO2011019929A1 (en) 2011-02-17
JP2013501942A (ja) 2013-01-17
EP3444613B1 (en) 2021-05-19
JP5823964B2 (ja) 2015-11-25
JP6105678B2 (ja) 2017-03-29
US20110038872A1 (en) 2011-02-17
US8383360B2 (en) 2013-02-26
CA2771102A1 (en) 2011-02-17
CN105911275A (zh) 2016-08-31
ES2875764T3 (es) 2021-11-11
CN102576022B (zh) 2016-06-15
US20170191994A1 (en) 2017-07-06
EP2464976A1 (en) 2012-06-20
DK2464976T3 (en) 2019-03-04
MX2019014978A (es) 2020-02-24
US20130210037A1 (en) 2013-08-15
DK3444613T3 (da) 2021-06-21
CN102576022A (zh) 2012-07-11
CA2771102C (en) 2019-10-15

Similar Documents

Publication Publication Date Title
MX2019014978A (es) Metodos de diagnostico de autismo in vitro.
Lozano-Ramos et al. Size-exclusion chromatography-based enrichment of extracellular vesicles from urine samples
Muralimanoharan et al. Sexual dimorphism in miR-210 expression and mitochondrial dysfunction in the placenta with maternal obesity
Lurbe et al. Developmental and early life origins of cardiometabolic risk factors: novel findings and implications
WO2011092592A3 (en) Methods and compositions for noninvasive prenatal diagnosis of fetal aneuploidies
WO2007140962A3 (en) Improved measurement of vitamin d
JP2013501942A5 (es)
WO2012012703A3 (en) Identification of differentially represented fetal or maternal genomic regions and uses thereof
WO2014132244A9 (en) Maternal plasma transcriptome analysis by massively parallel rna sequencing
WO2010078872A3 (en) Enrichment and identification of fetal cells in maternal blood and ligands for such use
Lasabová et al. Overexpression of miR-21 and miR-122 in preeclamptic placentas
WO2010129354A3 (en) Compositions and methods for detecting predisposition to a substance use disorder
WO2008132753A3 (en) Methods and kits for detecting fetal cells in the maternal blood
MX2022008215A (es) Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo.
Kotlabova et al. Extracellular chromosome 21-derived microRNAs in euploid & aneuploid pregnancies
DE602006013453D1 (de) Verfahren zur anreicherung fötaler zellen
Sakamoto et al. Retrospective study on temporal and regional variations of methylmercury concentrations in preserved umbilical cords collected from inhabitants of the Minamata area, Japan
Zhai et al. Alteration of podocyte phenotype in the urine of women with preeclampsia
AU2006214242A1 (en) Detection of biomarkers for neuropsychiatric disorders
Nishizawa-Jotaki et al. Association between mercury in cord serum and sex-specific DNA methylation in cord tissues
MX2019004207A (es) Un metodo de diagnostico complementario para el uso en el tratamiento del sindrome de intestino irritable con dietas de intervencion o trasplante de microbiota fecal.
Hogan et al. SFPQ intron retention, reduced expression and aggregate formation in central nervous system tissue are pathological features of amyotrophic lateral sclerosis
Jin et al. Comparative studies of two methods for miRNA isolation from milk whey
JP2018511047A5 (es)
Wang et al. Increased Circulating miR-155 identifies a subtype of preeclamptic patients

Legal Events

Date Code Title Description
FG Grant or registration